Literature DB >> 22094454

The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy.

Constantinos O'Mahony1, Pier D Lambiase, Shafiqur M Rahman, Montserrat Cardona, Margherita Calcagnino, Giovanni Quarta, Konstantinos Tsovolas, Shereen Al-Shaikh, William McKenna, Perry Elliott.   

Abstract

BACKGROUND: The triggers of ventricular arrhythmias (VAs) leading to sudden cardiac death in hypertrophic cardiomyopathy (HCM) are ill defined. We sought to examine the electrophysiological characteristics of VAs in HCM and study their relation to cardiac phenotype and circadian patterns using stored intracardiac electrocardiograms from implantable cardioverter defibrillators (ICDs). METHODS AND
RESULTS: A single centre, observational cohort study of 230 consecutively evaluated ICD recipients with HCM [median age 42 years, 97% primary prevention, 51% with anti-tachycardia pacing (ATP)]. Fifty-six non-clustered VAs (39 initially treated with ATP and 17 with shocks) from 29 patients were analysed. Monomorphic ventricular tachycardia was the culprit arrhythmia in 86% of cases, ventricular fibrillation/flutter in 9%, and polymorphic ventricular tachycardia in 5%. Prior to the onset of VA the rhythm was sinus in 67%, atrial fibrillation/flutter in 19%, and 15% were paced ventricularly; tachycardia (cycle length <600 ms) was present in 25%. Ventricular arrhythmias were triggered by premature ventricular complexes (PVCs) in 72%, which were late-coupled (84%). Short-long-short initiation was seen in 2% and 26% of VAs were sudden-onset without preceding PVCs. Ventricular arrhythmia peaked at midday (with 20% occurring between 2300 and 0700), on Sundays and in May. The cardiac phenotype and time of the day did not predict the mode of initiation. Age at ICD implantation was the only independent predictor of VA cycle length (linear regression coefficient 0.67, 95% CI 0.02-1.32, P= 0.04). Anti-tachycardia pacing terminated 67% of VAs, but patients with ATP therapy had a similar incidence of appropriate shocks (log-rank test P= 0.25) and syncope (log rank P= 0.23) to patients with shock as initial therapy.
CONCLUSIONS: Most VAs are monomorphic ventricular tachycardias triggered by late-coupled PVCs. They are frequently terminated by ATP, but ATP does not reduce the frequency of ICD shocks. Younger HCM patients have more rapid VAs, which may explain the peak of sudden cardiac death in early adulthood. The circadian periodicity is different from that observed in ischaemic heart disease, and is likely to relate to the distinct character of the arrhythmogenic substrate in HCM and its modulators.

Entities:  

Mesh:

Year:  2011        PMID: 22094454     DOI: 10.1093/europace/eur362

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  11 in total

Review 1.  Insights and challenges in hypertrophic cardiomyopathy, 2012.

Authors:  Srijita Sen-Chowdhry; María Teresa Tomé Esteban; William J McKenna
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-25

2.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

Review 3.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

4.  Effects of low-level hexabromocyclododecane (HBCD) exposure on cardiac development in zebrafish embryos.

Authors:  Meifang Wu; Zhenghong Zuo; Bowen Li; Lixing Huang; Meng Chen; Chonggang Wang
Journal:  Ecotoxicology       Date:  2013-08-01       Impact factor: 2.823

5.  Fibrosis and wall thickness affect ventricular repolarization dynamics in hypertrophic cardiomyopathy.

Authors:  Mikko Jalanko; Heikki Väänänen; Mika Tarkiainen; Petri Sipola; Pertti Jääskeläinen; Kirsi Lauerma; Tiina Laitinen; Tomi Laitinen; Mika Laine; Tiina Heliö; Johanna Kuusisto; Matti Viitasalo
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-07-04       Impact factor: 1.468

Review 6.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

7.  Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.

Authors:  Milena Leo; Alexander J Sharp; Andre Briosa E Gala; Michael T B Pope; Timothy R Betts
Journal:  J Interv Card Electrophysiol       Date:  2022-07-14       Impact factor: 1.759

8.  Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy.

Authors:  Emanuel Kaltenecker; Julia Schleihauf; Christian Meierhofer; Nerejda Shehu; Naira Mkrtchyan; Alfred Hager; Andreas Kühn; Julie Cleuziou; Karin Klingel; Heide Seidel; Martin Zenker; Peter Ewert; Gabriele Hessling; Cordula M Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

9.  Dual myosin binding protein C3 and potassium voltage-gated channel subfamily H member 2 co-inherited pathogenic variants in a patient with hypertrophic cardiomyopathy and long QT 2 syndrome: A case report.

Authors:  Chikezie K Alvarez; Emily Smith; Adaya Weissler-Snir
Journal:  HeartRhythm Case Rep       Date:  2021-12-16

10.  Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).

Authors:  Oliver P Guttmann; Menelaos Pavlou; Constantinos O'Mahony; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; Pablo Garcia-Pavia; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2015-07-16       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.